Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Dabrafenib · Tafinlar, GSK-2118436

Small molecule · Inhibitor of BRAF · developed by Novartis

Approved FDA, May 2013
NVS Developer

What is Dabrafenib?

Dabrafenib is a small-molecule kinase inhibitor of mutated BRAF kinases, including BRAF V600E, V600K and V600D, and also inhibits wild-type BRAF and CRAF. It blocks the RAS/RAF/MEK/ERK pathway and is studied in melanoma, non-small cell lung cancer, solid tumors and high-grade glioma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Tafinlar, GSK-2118436, GSK-2118436A
Drug type
Small molecule
Targets
BRAF, CRAF (RAF1) (secondary target)
Mechanism
Inhibitor of BRAF
Pathways
RAS/RAF/MEK/ERK pathway, MAPK pathway
Therapy area
Oncology
Developer
Novartis (NVS)
FDA status
Approved as Tafinlar (May 29, 2013), NDA202806 · FDA label
UNII
QGP4HA4G1B

✅ FDA-approved uses

From the indications section of the FDA label (version of May 20, 2026). Read the full label for the exact wording, limitations and safety information.

Conditions studied

High Grade GliomaMelanomaNon Small Cell Lung CancerRare CancersSolid Tumor

Other drugs acting on BRAF

More from Novartis

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Dabrafenib

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.